When will Big Pharma get serious about antibiotic R&D?

The 5 most promising antibiotic treatments in the industry's pipeline all have something in common: Not one was developed by Big Pharma. John LaMattina, former head of R&D at Pfizer ($PFE), pointed out in Forbes that companies like Cubist ($CBST), Basilea ​Pharmaceutica ($BSLN) and Otsuka are doing most of the late-stage heavy lifting in antibiotics, and, excluding Roche's ($RHHBY) recent re-entry to the field, most of the world's largest drugmakers are standing on the sidelines as so-called superbugs become all the more common. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.